Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cedarbaum, J. M.
Right arrow Articles by McDowell, F. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cedarbaum, J. M.
Right arrow Articles by McDowell, F. H.
NEUROLOGY 1987;37:233
© 1987 American Academy of Neurology

Controlled-release levodopa/carbidopa

I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease

Jesse M. Cedarbaum, MD, Lyn Breck, RN, Henn Kutt, MD and Fletcher H. McDowell, MD

Department of Neurology, The Burke Rehabilitation Center, White Plains, NY, and The New York Hospital-Cornell Medical Center, New York, NY.

Eight Parkinson patients with response fluctuations completed an open-label trial of a controlled-release carbidopa/levodopa preparation (Sinemet CR3). At the end of 6 weeks, percent "on" time and mean interdose interval increased, the number of daily doses and "off" periods was decreased, and the variability of plasma levodopa levels and disability scores was reduced. However, response fluctuations continued to occur, day-to-day consistency was poor, and the bioavailability of levodopa appeared less than that of standard Sinemet. Overall benefit waned over the next 3 to 6 months. Oral controlled-release carbidopa/levodopa is capable of reducing fluctuations in plasma levodopa levels and clinical performance in Parkinson's disease. The response to this particular controlled-release formulation was suboptimal and unsustained.

Address correspondence and reprint requests to Dr. Cedarbaum. The Burke Rehabilitation Center, 785 Mamaroneck Avenue, White Plains, NY 10605.

Received February 20, 1986. Accepted for publication May 9, 1986.

Supported in part by the Winnifred Masterson Burke Relief Foundation; the Harold G. and Leila Y. Mathers Charitable Foundation; PHS research grant RR0047 from the Division of Research Resources, NIH; and Merck Sharp & Dohme, Inc.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by AAN Enterprises, Inc.